PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia (Q39243194)

10 September 2017

title

PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia (English)

1 reference

10 September 2017

0 references

1 reference

D E Spaner

1

1 reference

10 September 2017

E Lee

2

1 reference

10 September 2017

Y Shi

3

1 reference

10 September 2017

F Wen

4

1 reference

10 September 2017

Y Li

5

1 reference

10 September 2017

S Tung

6

1 reference

10 September 2017

L McCaw

7

1 reference

10 September 2017

K Wong

8

1 reference

10 September 2017

H Gary-Gouy

9

1 reference

10 September 2017

A Dalloul

10

1 reference

10 September 2017

R Ceddia

11

1 reference

10 September 2017

R Gorzcynski

12

1 reference

10 September 2017

publication date

19 November 2012

1 reference

10 September 2017

1 reference

10 September 2017

volume

27

1 reference

10 September 2017

issue

5

1 reference

10 September 2017

page(s)

1090-1099

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2012.329

10 September 2017

exact match

0 references

cites work

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

Risk categories and refractory CLL in the era of chemoimmunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

VLDL hydrolysis by LPL activates PPAR-alpha through generation of unbound fatty acids

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

The biology of cancer: metabolic reprogramming fuels cell growth and proliferation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

Therapeutic targets in cancer cell metabolism and autophagy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

PPARs and lipid ligands in inflammation and metabolism

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

The androgen/androgen receptor axis in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

Clinical and Biochemical Effects of an Oral Leukotriene Biosynthesis Inhibitor (MK886) in Psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

Soluble CD200 is critical to engraft chronic lymphocytic leukemia cells in immunocompromised mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

Prolonging microtubule dysruption enhances the immunogenicity of chronic lymphocytic leukaemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

Prolonged exposure to palmitate impairs fatty acid oxidation despite activation of AMP-activated protein kinase in skeletal muscle cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

Natural phosphorylation of CD5 in chronic lymphocytic leukemia B cells and analysis of CD5-regulated genes in a B cell line suggest a role for CD5 in malignant phenotype

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

A novel Rag2-/-gammac-/--xenograft model of human CLL.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

Glucose represses PPARα gene expression via AMP-activated protein kinase but not via p38 mitogen-activated protein kinase in the pancreatic β-cell

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

Flicking the Warburg switch-tyrosine phosphorylation of pyruvate dehydrogenase kinase regulates mitochondrial activity in cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

Drug-mediated inhibition of Fli-1 for the treatment of leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

From pathogenesis to treatment of chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

Immunogenic and tolerogenic cell death

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

CD54 is a surrogate marker of antigen presenting cell activation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

Expression of the Peroxisome Proliferator-activated Receptor Gene Is Stimulated by Stress and Follows a Diurnal Rhythm

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

Research resource: Comparative nuclear receptor atlas: basal and activated peritoneal B-1 and B-2 cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

Characterization of a novel metabolic strategy used by drug-resistant tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

PPARalpha deficiency in inflammatory cells suppresses tumor growth

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.329

7 January 2021

Identifiers

DOI

10.1038/LEU.2012.329

1 reference

Dimensions Publication ID

10 September 2017

1022887457

0 references

1 reference